KalVista Pharmaceuticals announced it will present new EKTERLY data at the 2026 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting. The event will take place in Philadelphia from February 27 to March 2, 2026. The presentations highlight ongoing research into sebetralstat, an investigational oral therapy for hereditary angioedema (HAE).
The acceptance of three abstracts reflects KalVista’s continued focus on advancing treatment options for patients living with HAE. Additionally, the data will provide deeper insights into treatment response, attack management, and patient burden.
Clinical Insights From EKTERLY Data
Two poster presentations will occur on Friday, February 27, from 2:45–3:45 pm ET at the Convention Center, Level 2, Hall E.
The first poster examines response drivers observed in placebo-controlled clinical trials of sebetralstat. Researchers aim to identify factors that influence treatment effectiveness. As a result, clinicians may better understand which patients benefit most from on-demand therapy.
The second presentation analyzes treatment patterns from the KONFIDENT-S study. It focuses on how patients use sebetralstat during hereditary angioedema attacks. Furthermore, the findings could help optimize real-world treatment strategies and improve symptom control.
Late-Breaking Study on Hereditary Angioedema
A late-breaking, investigator-initiated poster will be presented on Sunday, March 1, from 9:45–10:45 am ET at the same venue.
This study shares results from the ECRINS survey, which evaluates attack management and the overall burden experienced by patients with hereditary angioedema. Moreover, the research highlights ongoing challenges in disease management while emphasizing the importance of faster, more reliable treatments.
Expanding Research in Rare Disease Care
KalVista continues to invest in innovative therapies that address unmet needs in rare diseases. Therefore, the upcoming presentations strengthen the company’s role in improving care for people affected by hereditary angioedema.
As scientific collaboration grows, meetings like AAAAI provide a platform for sharing breakthrough findings.
Overall, the latest EKTERLY data underline KalVista’s commitment to advancing oral treatment research and supporting better health outcomes for patients worldwide.
Read Also: Sandy Voss Appointment: Joins Life Science Connect as SVP
